	US 11,771,125 B1
	Concentrated nutritional or supplemental compound for intestinal, gut-brain axis and neurobiological homeostasis through calibrated absorption including neurotransmitter or any equilibrating compound release to treat or mitigate disease and co-morbidities, particularly obesity and malnourishment
Terry Earl Brady, The Valley (AI); Anthony Lee Dellinger, Burlington, NC (US); Lowell Hughes, The Valley (AI); and Melinda K. M. Goddard, The Valley (AI)
Filed by Terry Earl Brady, The Valley (AI); Anthony Lee Dellinger, Burlington, NC (US); Lowell Hughes, The Valley (AI); and Melinda K. M. Goddard, The Valley (AI)
Filed on Sep. 26, 2022, as Appl. No. 17/952,691.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A23L 33/00 (2016.01); A23L 33/185 (2016.01); A23L 33/19 (2016.01); A23L 15/00 (2016.01); A61K 9/14 (2006.01); A61K 9/48 (2006.01); A61K 31/655 (2006.01); A61K 9/28 (2006.01); A23L 33/175 (2016.01)

CPC A23L 33/30 (2016.08) [A23L 15/20 (2016.08); A23L 33/185 (2016.08); A23L 33/19 (2016.08); A61K 9/146 (2013.01); A61K 9/286 (2013.01); A61K 9/4858 (2013.01); A61K 31/655 (2013.01); A23L 33/175 (2016.08)]

16 Claims

1. An extended duration solid form dosage that stimulates homeostatic serotonin production, consisting essentially of:

a. Alginic acid encapsulated lyophilized whole egg powder;

b. Alginic acid encapsulated lyophilized whole milk powder;

c. in a pharmaceutically acceptable enteric form containing a protective coating;

wherein the solid form dosage is taken on an empty stomach.